Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · ANI Pharmaceuticals (ANIP)

ANI Pharmaceuticals files September 2025 investor presentation for two investor conferences

Neutral Impact 2 of 5 other Written later

ANI Pharmaceuticals furnished an updated investor presentation as Exhibit 99.1 for use at the H.C. Wainwright and Morgan Stanley healthcare conferences on September 8 and 9, 2025. The deck restates figures from the company's August 8, 2025 earnings release and does not report new full-year results, and the company says it is not reconfirming that guidance as of the presentation date.

Key points

  • Presentations at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025 and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025.
  • Deck restates 2025 guidance issued August 8, 2025: net revenue $818 million to $843 million and adjusted non-GAAP EBITDA $213 million to $223 million.
  • Deck cites Q2 2025 total revenue of $211 million, up 53% year over year, and Q2 adjusted non-GAAP EBITDA of $54 million.
  • The company states it is not reconfirming the August 8 guidance and assumes no obligation to update it.

The filing

CompanyANI Pharmaceuticals (ANIP)
Form8-K, current report
Filed with the SECSep 8, 2025, 6:57 AM ET
Accession number0001023024-25-000089

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:57 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 08, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.